Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2016-06-20
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor
cells.
PURPOSE: This randomized phase II trial is studying gemcitabine and imatinib mesylate to see
how well they work compared to gemcitabine alone in treating patients with previously treated
locally advanced or metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals Rutgers Cancer Institute of New Jersey